World Pharma Pricing & Market Access Congress 2018
20 - 21 March 2018
Join the Context Matters team onsite to learn more about our industry-leading market access intelligence solutions. and discover how our integration with Decision Resources Group provides enhanced end-to-end service options for market access. Plus, attend our data-driven presentation exploring assessment of combo-therapies for oncology.
Is There Bias in the Assessment of Combo-Therapies for Oncology?
Immuno Therapies and Combination Therapies
Are health technology assessment agencies treating high-cost novel agent combinations for Oncology differently than high-cost agents reviewed alone or with non-high-cost therapies? This presentation will employ a data-driven analysis of the decision rates to examine how agencies are reacting to combination therapies for oncology.
Tuesday, March 20
Vice President, Accounts & Analytics
Director, HealthTechnology Assessment